Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pluri has advanced several placenta-derived allogeneic cell therapies into late-stage clinical trials across multiple indications including muscle injury and hematologic conditions. The company’s proprietary 3D bioreactor system enables large-scale GMP manufacturing supporting these programs as well as CDMO services for external partners. Clinical results have demonstrated safety and potential efficacy in target indications but full pivotal data are not yet publicly available.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Pluri Mobile.